A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 18, 2015

Primary Completion Date

December 17, 2024

Study Completion Date

December 17, 2024

Conditions
Spinal Muscular Atrophy
Interventions
DRUG

Nusinersen

Solution for intrathecal injection

Trial Locations (21)

100

National Taiwan University Hospital, Taipei

165

Ospedale Pediatrico Bambino Gesù, Rome

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

3050

Hamad General Hospital, Doha

3052

Royal Children's Hospital, Parkville

4101

Queensland Children's Hospital, South Brisbane

6230

Hacettepe University Medical Faculty, Ankara

10032

Columbia University, New York

19104

The Children's Hospital of Philadelphia, Philadelphia

20162

Fondazione Serena Onlus - Centro Clinico Nemo, Milan

21205

The Johns Hopkins Hospital, Baltimore

31755

Yeditepe University Medical School Hospital, Istanbul

32827

Nemours Children's Hospital, Orlando, Orlando

79106

Universitaetsklinikum Freiburg, Freiburg im Breisgau

80045

Children's Hospital Colorado, Aurora

84112

University of Utah, Salt Lake City

90095

David Geffen School of Medicine, Los Angeles

95817

University of California Davis Health System, Sacramento

98101

Seattle Children's Research Institute, Seattle

60611-2605

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY